Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

Birrer MJ, Moore KN, Betella I, Bates RC.

J Natl Cancer Inst. 2019 Mar 11. pii: djz035. doi: 10.1093/jnci/djz035. [Epub ahead of print]

PMID:
30859213
2.

Evaluation of chromatofocusing as a capture method for monoclonal antibody products.

Liu Y, Deldari S, Guo H, Narahari CR, Bates RC, Swanson R, Ghose S, Li ZJ, Frey DD.

J Chromatogr A. 2018 Sep 21;1568:108-122. doi: 10.1016/j.chroma.2018.07.028. Epub 2018 Jul 6.

PMID:
30072232
3.

Increasing pro-survival factors within whole brain tissue of Sprague Dawley rats via intracerebral administration of modified valproic acid.

Bates RC, Stith BJ, Stevens KE.

J Pharmacol Sci. 2015 Aug;128(4):193-201. doi: 10.1016/j.jphs.2015.07.003. Epub 2015 Jul 28.

4.

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.

Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W.

Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13.

5.

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.

Liu Y, Ye J, Shin Ogawa L, Inoue T, Huang Q, Chu J, Bates RC, Ying W, Sonderfan AJ, Rao PE, Zhou D.

PLoS One. 2015 May 14;10(5):e0127361. doi: 10.1371/journal.pone.0127361. eCollection 2015.

6.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.

Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.

7.

Reduced CHRNA7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABA(A) receptor subunits.

Bates RC, Stith BJ, Stevens KE, Adams CE.

Neuroscience. 2014 Jul 25;273:52-64. doi: 10.1016/j.neuroscience.2014.05.004. Epub 2014 May 13.

8.

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.

Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta N, Knowles MA, Bates RC, Proia DA.

Mol Cancer Res. 2014 Jul;12(7):1042-54. doi: 10.1158/1541-7786.MCR-14-0004. Epub 2014 Apr 30.

9.

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.

He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA.

Invest New Drugs. 2014 Aug;32(4):577-86. doi: 10.1007/s10637-014-0095-4. Epub 2014 Apr 1.

10.

Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.

Proia DA, Bates RC.

Cancer Res. 2014 Mar 1;74(5):1294-300. doi: 10.1158/0008-5472.CAN-13-3263. Epub 2014 Feb 20. Review.

11.

mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.

Acquaviva J, He S, Sang J, Smith DL, Sequeira M, Zhang C, Bates RC, Proia DA.

Mol Cancer Res. 2014 May;12(5):703-13. doi: 10.1158/1541-7786.MCR-13-0605. Epub 2014 Feb 19.

12.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

13.

Activation of Src and release of intracellular calcium by phosphatidic acid during Xenopus laevis fertilization.

Bates RC, Fees CP, Holland WL, Winger CC, Batbayar K, Ancar R, Bergren T, Petcoff D, Stith BJ.

Dev Biol. 2014 Feb 1;386(1):165-80. doi: 10.1016/j.ydbio.2013.11.006. Epub 2013 Nov 21.

14.

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.

Proia DA, Zhang C, Sequeira M, Jimenez JP, He S, Spector N, Shapiro GI, Tolaney S, Nagai M, Acquaviva J, Smith DL, Sang J, Bates RC, El-Hariry I.

Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30.

15.

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Tatsuta N, Wada Y, Koya K, Huang Q, Bates RC, Sonderfan AJ.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):401-9. doi: 10.1016/j.taap.2013.09.018. Epub 2013 Oct 1.

16.

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA.

Cancer Discov. 2013 Apr;3(4):430-43. doi: 10.1158/2159-8290.CD-12-0440. Epub 2013 Mar 26.

17.

Chronic central administration of valproic acid: Increased pro-survival phospho-proteins and growth cone associated proteins with no behavioral pathology.

Bates RC, Stith BJ, Stevens KE.

Pharmacol Biochem Behav. 2012 Dec;103(2):237-44. doi: 10.1016/j.pbb.2012.08.023. Epub 2012 Aug 31.

PMID:
22960225
18.

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.

Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK.

PLoS One. 2011 Apr 14;6(4):e18552. doi: 10.1371/journal.pone.0018552.

19.

Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells.

Bates RC, Pursell BM, Mercurio AM.

Cells Tissues Organs. 2007;185(1-3):29-39. Review.

PMID:
17587805
20.

The association between CD36 and Lyn protein tyrosine kinase is mediated by lipid.

Thorne RF, Law EG, Elith CA, Ralston KJ, Bates RC, Burns GF.

Biochem Biophys Res Commun. 2006 Dec 8;351(1):51-6. Epub 2006 Oct 6.

PMID:
17052693
21.

The alphaVbeta6 integrin as a novel molecular target for colorectal cancer.

Bates RC.

Future Oncol. 2005 Dec;1(6):821-8. Review.

PMID:
16556062
22.

Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease.

Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM.

Cancer Res. 2005 Dec 1;65(23):10938-45.

23.
24.

The epithelial-mesenchymal transition (EMT) and colorectal cancer progression.

Bates RC, Mercurio AM.

Cancer Biol Ther. 2005 Apr;4(4):365-70. Epub 2005 Apr 4. Review.

PMID:
15846061
25.

Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.

Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM.

J Clin Invest. 2005 Feb;115(2):339-47.

26.

The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis.

Bates RC, DeLeo MJ 3rd, Mercurio AM.

Exp Cell Res. 2004 Oct 1;299(2):315-24.

PMID:
15350531
27.

Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin.

Mercurio AM, Bachelder RE, Bates RC, Chung J.

Semin Cancer Biol. 2004 Apr;14(2):115-22. Review.

PMID:
15018895
28.

Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids.

Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, Mercurio AM.

Curr Biol. 2003 Sep 30;13(19):1721-7.

29.

Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids.

Bates RC, Mercurio AM.

Mol Biol Cell. 2003 May;14(5):1790-800. Epub 2003 Jan 26.

30.
31.

Spheroids and cell survival.

Bates RC, Edwards NS, Yates JD.

Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):61-74. Review.

PMID:
11033297
32.
34.

Yet another finger and catheter saving tip for the tunnelled epidural catheter.

Bates RC.

Anaesthesia. 1999 Oct;54(10):1023. No abstract available.

35.

Engagement of variant CD44 confers resistance to anti-integrin antibody-mediated apoptosis in a colon carcinoma cell line.

Bates RC, Elith CA, Thorne RF, Burns GF.

Cell Adhes Commun. 1998 Jun;6(1):21-38.

PMID:
9759519
36.

This proud profession must heal itself.

Bates RC.

Med Econ. 1998 Oct 19;75(20):15-7, 21-2. No abstract available.

PMID:
10186268
38.

Loss of matrix adhesion triggers rapid transformation-selective apoptosis in fibroblasts.

McGill G, Shimamura A, Bates RC, Savage RE, Fisher DE.

J Cell Biol. 1997 Aug 25;138(4):901-11.

39.

Factor H co-purifies with thrombospondin isolated from platelet secretate.

Carron JA, Bates RC, Smith AI, Tetoz T, Arellano A, Gordon DL, Burns GF.

Biochim Biophys Acta. 1996 Apr 17;1289(3):305-11.

PMID:
8620012
40.

Multiplicity of fibronectin-binding alpha V integrin receptors in colorectal cancer.

Agrez MV, Bates RC, Mitchell D, Wilson N, Ferguson N, Anseline P, Sheppard D.

Br J Cancer. 1996 Apr;73(7):887-92.

41.

Involvement of integrins in cell survival.

Bates RC, Lincz LF, Burns GF.

Cancer Metastasis Rev. 1995 Sep;14(3):191-203. Review.

PMID:
8548868
42.

Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment.

Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD.

J Virol. 1995 Jun;69(6):3873-7.

43.

Let my people go.

Bates RC.

Med Econ. 1994 Oct 10;71(19):58-60, 62. No abstract available.

PMID:
10141907
44.

A retired physician speaks out. Let my people go.

Bates RC.

Mich Med. 1994 Jun;93(6):40-3. No abstract available.

PMID:
8057966
45.

Apoptosis induced by inhibition of intercellular contact.

Bates RC, Buret A, van Helden DF, Horton MA, Burns GF.

J Cell Biol. 1994 Apr;125(2):403-15.

46.
47.
48.

Health locus of control and self-efficacy beliefs in a healthy elderly sample.

Waller KV, Bates RC.

Am J Health Promot. 1992 Mar-Apr;6(4):302-9.

PMID:
10148754
49.
50.

Supplemental Content

Loading ...
Support Center